Cargando…

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells

BACKGROUND: Whether there is a mechanistic link between FOLR1 and response to cisplatin has not been extensively examined. In this study, we determine the expression of FOLR1 in ovarian cancer and examine if FOLR1 levels influence response to cisplatin. RESULTS: (1) FOLR1 protein expression was lowe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Ming-ju, Zhang, Wei, Wang, Qi, Yang, Zhi-jun, Liao, Sheng-bin, Li, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809985/ https://www.ncbi.nlm.nih.gov/pubmed/29433550 http://dx.doi.org/10.1186/s13048-018-0387-y

Ejemplares similares

Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer
por: Liang, Zhen, et al.
Publicado: (2021)

Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1–antibody-drug conjugate
por: Tang, Thao, et al.
Publicado: (2022)

Lumiflavin increases the sensitivity of ovarian cancer stem‐like cells to cisplatin by interfering with riboflavin
por: Yang, Ruhui, et al.
Publicado: (2019)

Site-specific glycoproteomic analysis revealing increased core-fucosylation on FOLR1 enhances folate uptake capacity of HCC cells to promote EMT
por: Jia, Li, et al.
Publicado: (2021)

Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
por: Necela, Brian M., et al.
Publicado: (2015)

Isoalantolactone Increases the Sensitivity of Prostate Cancer Cells to Cisplatin Treatment by Inducing Oxidative Stress
por: Huang, Hang, et al.
Publicado: (2021)

The Inhibitory Effect of Doxycycline on Cisplatin-Sensitive and -Resistant Epithelial Ovarian Cancer
por: Wu, Wei, et al.
Publicado: (2014)

Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer
por: Kim, Minsung, et al.
Publicado: (2018)

High Expression of Folate Receptor Alpha (FOLR1) is Associated With Aggressive Tumor Behavior, Poor Response to Chemoradiotherapy, and Worse Survival in Rectal Cancer
por: Chen, Chih-I, et al.
Publicado: (2022)

Correction: Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
por: Necela, Brian M., et al.
Publicado: (2015)

Retraction: The Inhibitory Effect of Doxycycline on Cisplatin-Sensitive and -Resistant Epithelial Ovarian Cancer
por: Wu, Wei, et al.
Publicado: (2020)

Differentially expressed genes in embryonic cardiac tissues of mice lacking Folr1 gene activity
por: Zhu, Huiping, et al.
Publicado: (2007)

lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer
por: Li, Qing, et al.
Publicado: (2018)

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study
por: Köbel, M, et al.
Publicado: (2014)

Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer
por: Xia, Xi, et al.
Publicado: (2011)

Reinforcing one-carbon metabolism via folic acid/Folr1 promotes β-cell differentiation
por: Karampelias, Christos, et al.
Publicado: (2021)

HSP27 Knockdown Increases Cytoplasmic p21 and Cisplatin Sensitivity in Ovarian Carcinoma Cells
por: Lu, Hao, et al.
Publicado: (2016)

Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles
por: Xiong, Xunhao, et al.
Publicado: (2014)

TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
por: Qi, Gonghua, et al.
Publicado: (2021)

FolR1: a novel cell surface marker for isolating midbrain dopamine neural progenitors and nascent dopamine neurons
por: Gennet, Nicole, et al.
Publicado: (2016)

Silencing of NLRP3 Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin
por: Li, Weijia, et al.
Publicado: (2023)

Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers
por: Notaro, Sara, et al.
Publicado: (2016)

CIC de novo loss of function variants contribute to cerebral folate deficiency by downregulating FOLR1 expression
por: Cao, Xuanye, et al.
Publicado: (2021)

FOLR1-induced folate deficiency reduces viral replication via modulating APOBEC3 family expression
por: Wu, Jing, et al.
Publicado: (2023)

Tripterygium glycosides sensitizes cisplatin chemotherapeutic potency by modulating gut microbiota in epithelial ovarian cancer
por: Zhan, Xinlu, et al.
Publicado: (2023)

Ghrelin enhances cisplatin sensitivity in HO-8910 PM human ovarian cancer cells
por: Leng, Yun, et al.
Publicado: (2021)

Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51
por: Wang, Bingliang, et al.
Publicado: (2015)

ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids
por: Hedemann, Nina, et al.
Publicado: (2021)

Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer
por: Fedoseienko, Alina, et al.
Publicado: (2016)

Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
por: Chilà, Rosaria, et al.
Publicado: (2022)

Folic acid modifies the shape of epithelial cells during morphogenesis via a Folr1 and MLCK dependent mechanism
por: Martin, Jessica B., et al.
Publicado: (2019)

Single-cell profiling reveals the trajectory of FOLR2-expressing tumor-associated macrophages to regulatory T cells in the progression of lung adenocarcinoma
por: Xiang, Chan, et al.
Publicado: (2023)

Arenobufagin increases the sensitivity of gastric cancer to cisplatin via alkaliptosis
por: Liu, Chengwei, et al.
Publicado: (2023)

Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells
por: Matsunaga, Yuki, et al.
Publicado: (2021)

NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
por: Huang, Jin-Cheng, et al.
Publicado: (2017)

Aspirin inhibits tumor progression and enhances cisplatin sensitivity in epithelial ovarian cancer
por: Guo, Jianfeng, et al.
Publicado: (2021)

NOXA-Induced Alterations in the Bax/Smac Axis Enhance Sensitivity of Ovarian Cancer Cells to Cisplatin
por: Lin, Chao, et al.
Publicado: (2012)

Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer
por: XIE, YA, et al.
Publicado: (2014)

Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors
por: Rodrigues Moita, Ana J., et al.
Publicado: (2020)

First case report of cerebral folate deficiency caused by a novel mutation of FOLR1 gene in a Chinese patient
por: Zhang, Ciliu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jhqpkf7i01qlf28kj1js16q8qb